Low-dose naltrexone (LDN) represents a therapeutic intervention for long COVID based on mechanistic insights and clinical benefits across multiple observational studies. The evidence demonstrates biological rationale through restoration of TRPM3 ion channel function and anti-inflammatory effects, supported by symptom improvements across independent research groups. However, no completed randomized controlled trials exist—all current evidence derives from observational studies.